Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

Acrivon Therapeutics, Inc. Common Stock

Healthcare US ACRV

1.625USD
-0.005(0.31%)

Last update at 2026-06-24T17:46:00Z

Day Range

1.621.70
LowHigh

52 Week Range

1.053.56
LowHigh

Fundamentals

  • Previous Close 1.63
  • Market Cap68.19M
  • Volume193176
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-82.75800M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-2.02

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -77.90500M -80.55600M -60.38800M -31.16700M -16.24300M
Minority interest - - - - -
Net income -77.90500M -80.55600M -60.38800M -29.67700M -16.24300M
Selling general administrative 24.12M 25.21M 21.08M 8.71M 2.47M
Selling and marketing expenses - - 0.13M - -
Gross profit -1.35600M -1.00600M -0.53600M - -
Reconciled depreciation 1.36M 1.01M 0.51M 0.36M 0.04M
Ebit -84.11400M -80.55600M -60.38800M -33.02100M -16.18400M
Ebitda -82.75800M -79.55000M -59.85200M -32.65700M -16.14700M
Depreciation and amortization 1.36M 1.01M 0.54M 0.36M 0.04M
Non operating income net other - - - 1.49M -
Operating income -84.11400M -89.19900M -67.23700M -32.65700M -16.18400M
Other operating expenses 84.11M 89.20M 67.24M 32.66M 16.18M
Interest expense - - - -1.49000M 0.06M
Tax provision - - - - -
Interest income 6.48M 9.20M 7.04M - -
Net interest income 6.48M 9.20M 7.04M - -
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - - 0.00000M -1.49000M 0.06M
Total revenue 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Total operating expenses 82.76M 88.19M 66.70M 32.66M 16.18M
Cost of revenue 1.36M 1.01M 0.54M - -
Total other income expense net 6.21M 8.64M 6.85M 1.49M -0.05900M
Discontinued operations - - - - -
Net income from continuing ops -77.90500M -80.55600M -50.06500M -31.16700M -16.24300M
Net income applicable to common shares - - - -31.16700M -16.24300M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 129.72M 196.59M 138.26M 181.23M 106.59M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 1.86M 2.15M 2.23M 4.34M 0.81M
Total liab 17.20M 19.80M 17.07M 10.75M 130.40M
Total stockholder equity 112.52M 176.79M 121.19M 170.47M -23.80900M
Deferred long term liab - - - - -
Other current liab 12.21M 15.40M 7.38M 4.82M 1.22M
Common stock 0.03M 0.03M 0.02M 0.02M 0.00200M
Capital stock 0.03M 0.03M 0.02M 0.02M 0.00200M
Retained earnings -274.88100M -196.97600M -116.42000M -56.03200M -24.86500M
Other liab - - - - -
Good will - - - - -
Other assets - - 0.00000M 0.39M 0.39M
Cash 41.50M 39.82M 36.02M 29.52M 99.60M
Cash and equivalents - - - - -
Total current liabilities 15.66M 17.21M 13.30M 6.52M 2.91M
Current deferred revenue - - - 0.07M 0.07M
Net debt -38.79000M -36.17300M -31.37100M -24.55800M -93.97500M
Short term debt 1.17M 1.06M 0.88M 0.73M 0.66M
Short long term debt - - - - -
Short long term debt total 2.71M 3.65M 4.64M 4.96M 5.63M
Other stockholder equity 387.25M 373.28M 237.68M 45.35M 1.05M
Property plant equipment - - - 2.09M 5.79M
Total current assets 120.44M 181.63M 129.69M 127.75M 100.41M
Long term investments 0.00000M 5.09M 0.00000M 41.88M -
Net tangible assets - - - 170.47M -23.80900M
Short term investments 77.08M 139.66M 91.44M 98.23M -
Net receivables - - - - -
Long term debt - - - - -
Inventory - - - - -
Accounts payable 2.28M 0.76M 5.05M 0.90M 0.96M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 0.11M 0.45M -0.08300M -0.09500M -
Additional paid in capital - - - - -
Common stock total equity - - - 0.02M -
Preferred stock total equity - - - - -
Retained earnings total equity - - - -56.03200M -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 1.86M 1.84M 0.25M 4.73M 0.39M
Deferred long term asset charges - - - - -
Non current assets total 9.27M 14.96M 8.57M 53.48M 6.18M
Capital lease obligations 2.71M 3.65M 4.64M 4.96M 5.63M
Long term debt total - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 67.77M -51.77100M -64.88600M -139.51000M -0.23800M
Change to liabilities - - - -0.24500M 0.80M
Total cashflows from investing activities 66.10M -51.77100M 50.72M -141.67600M -0.23800M
Net borrowings - - - - -
Total cash from financing activities -0.74900M 121.03M -1.55400M 101.71M 112.22M
Change to operating activities - - - - -0.47000M
Net income -77.90500M -80.55600M -60.38800M -31.16700M -16.24300M
Change in cash 1.69M 3.59M 6.52M -70.08400M 98.00M
Begin period cash flow 40.02M 36.43M 29.91M 99.99M 1.99M
End period cash flow 41.70M 40.02M 36.43M 29.91M 99.99M
Total cash from operating activities -63.66500M -65.66900M -42.64100M -30.11700M -13.98200M
Issuance of capital stock 0.00000M 70.00M 0.00000M 104.46M 112.22M
Depreciation 0.92M 1.01M 0.54M 0.36M 0.04M
Other cashflows from investing activities - - - - -
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables - - - - -
Sale purchase of stock - - - 101.71M -
Other cashflows from financing activities -0.75000M 51.03M -1.29700M -2.74900M -0.23800M
Change to netincome - - - 2.19M 1.90M
Capital expenditures 1.67M 2.77M 1.29M 2.17M 0.24M
Change receivables - - - - -
Cash flows other operating - - - -0.55600M -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - -70.08400M -
Change in working capital -2.42600M 2.44M 8.14M -1.53200M 0.33M
Stock based compensation 14.72M 14.29M 11.62M 2.19M 0.50M
Other non cash items 1.03M -2.84500M 1.06M 0.03M 1.14M
Free cash flow -65.33400M -68.43700M -43.92900M -32.28300M -14.22000M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to EBITDA (x)
ACRV
Acrivon Therapeutics, Inc. Common Stock		 -0.005 0.31% 1.62 - - - 0.64 -0.4267
NVO
Novo Nordisk A/S		 0.03 0.05% 47.45 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 - -% 46.84 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 8.43 1.80% 476.85 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 7.92 1.28% 625.95 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Acrivon Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops oncology medicines for patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its generative phosphoproteomics platform. The company operates Acrivon Predictive Precision Proteomics (AP3), a precision medicine platform that enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2 for the treatment of patients with endometrial and platinum-resistant ovarian cancer, and SCCs, such as SCCHN and anal cancer. The company is also developing ACR-2316, a dual WEE1 and PKMYT1 inhibitor small molecule candidate; and a preclinical stage AP3-and co-crystallography-based preclinical cell cycle program. The company was incorporated in 2018 and is based in Watertown, Massachusetts.

Acrivon Therapeutics, Inc. Common Stock

480 Arsenal Way, Watertown, MA, United States, 02472

Key Executives

Name Title Year Born
Dr. Peter Blume-Jensen M.D., Ph.D. Co-Founder, Chairman, CEO, Pres & Acting Chief Scientific Officer 1962
Ms. Kristina Masson Ph.D. Co-Founder, Exec. VP of Bus. Operations, Treasurer, Sec. & Director 1980
Dr. Eric J. Devroe Ph.D. Chief Operating Officer 1978
Mr. Erick Gamelin M.D., Ph.D. Chief Medical Officer 1957
Mr. Rasmus Holm-Jorgensen Chief Financial Officer 1971
Ms. Katharine Peterson CPA VP of Fin. & Accounting NA
Mr. Bruce Close VP of Quality & Compliance NA
Ms. Mary-Alice Miller J.D. Gen. Counsel 1974
Ms. Crystal Mercado Global Head of HR NA
Dr. Jesper V. Olsen Ph.D. Academic Co-Founder, Head of Phosphoproteomics & Member of Scientific Advisory Board NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.